Streetbeat News

Analyst Ratings

DUK

BMO Capital has maintained an 'Outperform' rating on Duke Energy and raised its price target from $120 to $126, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:57 pm

EA

Benchmark analyst Mike Hickey has reiterated a Buy rating on Electronic Arts (NASDAQ:EA) and maintained a price target of $163.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:53 pm

VFC

Barclays analyst Adrienne Yih has upgraded VF Corporation (NYSE:VFC) from Equal-Weight to Overweight and increased the price target from $19 to $22.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:52 pm

VSCO

Barclays analyst Adrienne Yih has upgraded Victoria's Secret (NYSE:VSCO) from Underweight to Equal-Weight and increased the price target from $23 to $25.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:48 pm

CIVI

JP Morgan has initiated coverage on Civitas Resources with an Overweight rating and set a price target of $67.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:37 pm

CRGY

JP Morgan has initiated coverage on Crescent Energy with a Neutral rating and set a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:34 pm

MGNI

Benchmark analyst Daniel Kurnos has reiterated a Buy rating on Magnite (NASDAQ:MGNI) and maintained a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:34 pm

NUTX

Maxim Group has initiated coverage on Nutex Health with a Buy rating and set a price target of $45. This suggests a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:33 pm

CMPO

Benchmark analyst Mark Palmer has maintained a Buy rating on CompoSecure (NASDAQ:CMPO) and raised the price target from $12 to $17.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:32 pm

CGEM

Wedbush analyst Robert Driscoll has reiterated an Outperform rating for Cullinan Therapeutics (NASDAQ:CGEM) and maintained a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:23 pm